ABSTRACT
OBJECTIVE: To develop an intelligent model for differential diagnosis of atrioventricular nodal re-entrant tachycardia (AVNRT) and atrioventricular re-entrant tachycardia (AVRT) using 12-lead wearable electrocardiogram devices. METHODS: A total of 356 samples of 12-lead supraventricular tachycardia (SVT) electrocardiograms recorded by wearable devices were randomly divided into training and validation sets using 5-fold cross validation to establish the intelligent classification model, and 101 patients with the diagnosis of SVT undergoing electrophysiological studies and radiofrequency ablation from October, 2021 to March, 2023 were selected as the testing set. The changes in electrocardiogram parameters before and during induced tachycardia were compared. Based on multiscale deep neural network, an intelligent diagnosis model for classifying SVT mechanisms was constructed and validated. The 3-lead electrocardiogram signals from â ¡, â ¢, and â ¤1 were extracted to build new classification models, whose diagnostic efficacy was compared with that of the 12-lead model. RESULTS: Of the 101 patients with SVT in the testing set, 68 were diagnosed with AVNRT and 33 were diagnosed with AVRT by electrophysiological study. The pre-trained model achieved a high area under the precision-recall curve (0.9492) and F1 score (0.8195) for identifying AVNRT in the validation set. The total F1 scores of the lead â ¡, â ¢, â ¤1, 3-lead and 12-lead intelligent diagnostic models in the testing set were 0.5597, 0.6061, 0.3419, 0.6003 and 0.6136, respectively. Compared with the 12-lead classification model, the lead-â ¢ model had a net reclassification index improvement of -0.029 (P=0.878) and an integrated discrimination index improvement of -0.005 (P=0.965). CONCLUSION: The intelligent diagnostic model based on multiscale deep neural network using wearable electrocardiogram devices has an acceptable accuracy for classifying SVT mechanisms.
Subject(s)
Electrocardiography , Tachycardia, Supraventricular , Wearable Electronic Devices , Humans , Electrocardiography/methods , Electrocardiography/instrumentation , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/classification , Tachycardia, Supraventricular/physiopathology , Diagnosis, Differential , Tachycardia, Atrioventricular Nodal Reentry/diagnosis , Tachycardia, Atrioventricular Nodal Reentry/classification , Tachycardia, Atrioventricular Nodal Reentry/physiopathology , Neural Networks, Computer , Female , MaleABSTRACT
Importance: Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective: To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants: An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention: Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures: Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results: Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS (P < .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases (P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance: There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.
Subject(s)
Electrocardiography , Humans , Mice , Case-Control Studies , Male , Animals , Female , Adult , Tachycardia, Ventricular/diagnosis , Tachycardia, Ventricular/physiopathology , Tachycardia, Ventricular/etiology , Heart Arrest/etiology , Heart Arrest/diagnosis , Calcium/metabolism , Calcium/blood , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/etiology , Middle Aged , Disease Models, Animal , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/etiology , Adolescent , Young Adult , Ryanodine Receptor Calcium Release Channel/geneticsABSTRACT
AIMS: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF). This study aimed to investigate the outcomes of catheter ablation (CA) for AF/AFL/AT in patients with ATTRwt-CM and propose a treatment strategy for CA. METHODS AND RESULTS: A cohort study was conducted on 233 patients diagnosed with ATTRwt-CM, including 54 who underwent CA for AF/AFL/AT. The background of each arrhythmia and the details of the CA and its outcomes were investigated. The recurrence-free rate of AF/AFL/AT overall in ATTRwt-CM patients with multiple CA was 70.1% at 1-year, 57.6% at 2-year, and 44.0% at 5-year follow-up, but CA significantly reduced all-cause mortality [hazard ratio (HR): 0.342, 95% confidence interval (CI): 0.133-0.876, P = 0.025], cardiovascular mortality (HR: 0.378, 95% CI: 0.146-0.981, P = 0.045), and HF hospitalization (HR: 0.488, 95% CI: 0.269-0.889, P = 0.019) compared with those without CA. There was no recurrence of the cavotricuspid isthmus (CTI)-dependent AFL, non-CTI-dependent simple AFL terminated by one linear ablation, and focal AT originating from the atrioventricular (AV) annulus or crista terminalis eventually. Twelve of 13 patients with paroxysmal AF and 27 of 29 patients with persistent AF did not have recurrence as AF. However, all three patients with non-CTI-dependent complex AFL not terminated by a single linear ablation and 10 of 13 cases with focal AT or multiple focal ATs originating beyond the AV annulus or crista terminalis recurred even after multiple CA. CONCLUSION: The outcomes of CA for ATTRwt-CM were acceptable, except for multiple focal AT and complex AFL. Catheter ablation may be aggressively considered as a treatment strategy with the expectation of improving mortality and hospitalization for HF.
Subject(s)
Amyloid Neuropathies, Familial , Atrial Fibrillation , Atrial Flutter , Cardiomyopathies , Catheter Ablation , Humans , Catheter Ablation/adverse effects , Male , Atrial Flutter/surgery , Atrial Flutter/etiology , Female , Atrial Fibrillation/surgery , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Aged , Amyloid Neuropathies, Familial/surgery , Amyloid Neuropathies, Familial/complications , Amyloid Neuropathies, Familial/mortality , Cardiomyopathies/mortality , Cardiomyopathies/therapy , Treatment Outcome , Middle Aged , Recurrence , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/etiology , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnosis , Retrospective Studies , Prealbumin/genetics , Prealbumin/metabolismABSTRACT
OBJECTIVE: Non-sustained supraventricular tachycardia (nsSVT) is associated with a higher risk of developing atrial fibrillation (AF), and, therefore, detection of nsSVT can improve AF screening efficiency. However, the detection is challenged by the lower signal quality of ECGs recorded using handheld devices and the presence of ectopic beats which may mimic the rhythm characteristics of nsSVT. METHODS: The present study introduces a new nsSVT detector for use in single-lead, 30-s ECGs, based on the assumption that beats in an nsSVT episode exhibits similar morphology, implying that episodes with beats of deviating morphology, either due to ectopic beats or noise/artifacts, are excluded. A support vector machine is used to classify successive 5-beat sequences in a sliding window with respect to similar morphology. Due to the lack of adequate training data, the classifier is trained using simulated ECGs with varying signal-to-noise ratio. In a subsequent step, a set of rhythm criteria is applied to similar beat sequences to ensure that episode duration and heart rate is acceptable. RESULTS: The performance of the proposed detector is evaluated using the StrokeStop II database, resulting in sensitivity, specificity, and positive predictive value of 84.6%, 99.4%, and 18.5%, respectively. CONCLUSION: The results show that a significant reduction in expert review burden (factor of 6) can be achieved using the proposed detector.Clinical and Translational Impact: The reduction in the expert review burden shows that nsSVT detection in AF screening can be made considerably more efficiently.
Subject(s)
Atrial Fibrillation , Electrocardiography , Signal Processing, Computer-Assisted , Support Vector Machine , Tachycardia, Supraventricular , Humans , Atrial Fibrillation/diagnosis , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/physiopathology , Electrocardiography/methods , Electrocardiography/instrumentationABSTRACT
BACKGROUND: Differentiation between ventricular tachycardia (VT) and supraventricular tachycardia (SVT) with aberrancy based on the 12lead ECG alone can be imprecise. Implantable cardiac defibrillators (ICD) may be inserted for presumed VT, particularly in patients with syncopal presentation or atypical aberrancy patterns. Accurate diagnosis of these patients facilitated by an electrophysiology study (EPS) may alter diagnosis and management. METHODS: We present a prospective collection of cases across 3 cardiac centers of consecutive patients with WCT presumed to be VT who were referred for consideration of an ICD, and in whom further evaluation including an EPS ultimately demonstrated SVT with aberrancy as the culprit arrhythmia. RESULTS: 22 patients were identified (17 male, mean age 50±13 years. Available rhythm data at the time of referral was presumptively diagnosed as monomorphic VT in 16 patients and polymorphic VT in 6 patients. Underlying structural heart disease was present in 20 (91%). EPS resulted in a diagnosis of SVT with aberrancy in all cases: comprising AV nodal re-entry tachycardia (n=10), orthodromic reciprocating tachycardia (n=3), focal atrial tachycardia (n=3), AF/AFL (n=3) and 'double fire' tachycardia (n=2). 21 (95%) patients underwent successful ablation. All patients remained free of arrhythmia recurrence at a median of 3.4 years of follow-up. ICD insertion was obviated in 18 (82%) patients, with 1 patient proceeding to ICD extraction. CONCLUSION: SVT with atypical aberrancy may mimic monomorphic or polymorphic VT. Careful examination of all available rhythm data and consideration of an EPS can confirm SVT and obviate the need for ICD therapy.
Subject(s)
Electrocardiography , Electrophysiologic Techniques, Cardiac , Tachycardia, Ventricular , Humans , Male , Middle Aged , Female , Tachycardia, Ventricular/diagnosis , Tachycardia, Ventricular/physiopathology , Diagnosis, Differential , Prospective Studies , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/physiopathologySubject(s)
Electrocardiography , Tachycardia, Supraventricular , Humans , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnosis , Male , Female , Middle Aged , Tachycardia, Paroxysmal/physiopathology , Tachycardia, Paroxysmal/diagnosis , Adult , Diagnosis, DifferentialABSTRACT
INTRODUCTION: There is a lack of studies in the literature directly investigating the relationship between atrial tachycardia (AT) and left atrial (LA)/left atrial appendage (LAA) thrombus, and current guidelines do not provide strong recommendations regarding the use of transesophageal echocardiography (TEE) before AT catheter ablation. This study aims to elucidate the relationship between AT and the presence of LA/LAA thrombus and contribute to the literature on the use of TEE before AT catheter ablation. METHODS: This single-center retrospective observational study screened patients who underwent TEE between February 10, 2019, and February 10, 2023. Patients were assigned to the AT patient and control groups. TEE was conducted to exclude thrombus in the AT ablation group. The control group included patients who underwent TEE for interatrial septum evaluation and had LA imaging during TEE but did not have atrial arrhythmia. To mitigate bias between the AT patient group and the control group, they were randomized 1:1 using propensity-score matching (PSM). Following randomization, each group consisted of 49 patients. RESULTS: All analyses were conducted after PSM. There were no statistically significant differences between the AT patient and control groups in terms of baseline clinical characteristics and echocardiographic features. Additionally, no significant differences were found between the blood viscosities calculated at low and high shear rates in both groups. The study revealed a significant difference between the two groups in the presence of LA spontaneous echo contrast (SEC) (24.5% in AT group vs 0% in Control group, p = .001), but not in the presence of thrombi (8.2% in AT group vs 0% in Control group, p = .117). CONCLUSION: Compared to the control group, the presence of SEC was significantly higher in the AT patient group. The increased frequency of SEC in AT patients suggests the hypothesis that AT may contribute to LA stasis. The routine use of TEE before AT catheter ablation remains controversial, despite the presence of LA thrombus and SEC in the AT patient group. The clinical assessment of thrombus presence before the procedure must be conducted on a patient-specific basis.
Subject(s)
Atrial Appendage , Catheter Ablation , Echocardiography, Transesophageal , Predictive Value of Tests , Tachycardia, Supraventricular , Thrombosis , Humans , Female , Male , Retrospective Studies , Middle Aged , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnostic imaging , Tachycardia, Supraventricular/diagnosis , Treatment Outcome , Aged , Atrial Appendage/diagnostic imaging , Atrial Appendage/physiopathology , Atrial Appendage/surgery , Thrombosis/diagnostic imaging , Adult , Heart Diseases/diagnostic imaging , Heart Diseases/physiopathology , Heart Diseases/surgery , Heart Rate , Action Potentials , Risk FactorsABSTRACT
INTRODUCTION: The impact of early recurrence of atrial tachyarrhythmia (ERAT) within the 90-day blanking period on long-term outcomes in atrial fibrillation (AF) patients undergoing cryoballoon ablation (CBA) is controversial. This study aimed to assess the relationship between ERAT and late recurrence of atrial tachyarrhythmia (LRAT) post-CBA. METHODS: Utilizing data from a multicenter registry in Korea (May 2018 to June 2022), we analyzed the presence and timing of ERAT (<30, 30-60, and 60-90 days) and its association with LRAT risk after CBA. LRAT was defined as any recurrence of AF, atrial flutter, or atrial tachycardia lasting more than 30 s beyond the 90 days. RESULTS: Out of 2636 patients, 745 (28.2%) experienced ERAT post-CBA. Over an average follow-up period of 21.2 ± 10.3 months, LRAT was observed in 874 (33.1%) patients. Patients with ERAT had significantly lower 1-year LRAT freedom compared to those without ERAT (42.6% vs. 85.5%, p < .001). Multivariate analysis identified ERAT as a potential predictor of LRAT, with a hazard ratio (HR) of 3.98 (95% confidence interval [CI], 3.47-4.57). Significant associations were noted across all examined time frames (HR, 3.84; 95% CI, 3.32-4.45 in <30 days, HR, 5.53; 95% CI, 4.13-7.42 in 30-60 days, and HR, 4.29; 95% CI, 3.12-5.89 in 60-90 days). This finding was consistently observed across all types of AF. CONCLUSION: ERAT during the 90-day blanking period strongly predicts LRAT in AF patients undergoing CBA, indicating a need to reconsider the clinical significance of this period.
Subject(s)
Atrial Fibrillation , Cryosurgery , Heart Rate , Recurrence , Registries , Humans , Atrial Fibrillation/surgery , Atrial Fibrillation/physiopathology , Atrial Fibrillation/diagnosis , Male , Female , Cryosurgery/adverse effects , Middle Aged , Time Factors , Aged , Risk Factors , Republic of Korea/epidemiology , Risk Assessment , Retrospective Studies , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/etiology , Action Potentials , Treatment Outcome , Pulmonary Veins/surgery , Pulmonary Veins/physiopathologyABSTRACT
A 34-year-old woman presented with palpitations and paroxysmal atrial fibrillation (AF). Workup revealed anterior mitral valve prolapse with severe mitral regurgitation. She was referred for surgical repair and underwent a mitral valve replacement, tricuspid valve repair, and bi-atrial cryoMAZE procedure with left atrial appendage ligation. Her postoperative course was complicated by inferior wall myocardial infarction. She subsequently presented with palpitations and underwent electrophysiology study and ablation. This case illustrates pitfalls associated with the surgical MAZE procedure and highlights the challenges in postoperative atrial arrhythmias diagnosis and management.
Subject(s)
Atrial Fibrillation , Maze Procedure , Humans , Atrial Fibrillation/surgery , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Female , Adult , Diagnosis, Differential , Postoperative Complications/diagnosis , Catheter Ablation/adverse effects , Electrocardiography , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/surgeryABSTRACT
INTRODUCTION: Ablation of scar-related reentrant atrial tachycardia (SRRAT) involves identification and ablation of a critical isthmus. A graph convolutional network (GCN) is a machine learning structure that is well-suited to analyze the irregularly-structured data obtained in mapping procedures and may be used to identify potential isthmuses. METHODS: Electroanatomic maps from 29 SRRATs were collected, and custom electrogram features assessing key tissue and wavefront properties were calculated for each point. Isthmuses were labeled off-line. Training data was used to determine the optimal GCN parameters and train the final model. Putative isthmus points were predicted in the training and test populations and grouped into proposed isthmus areas based on density and distance thresholds. The primary outcome was the distance between the centroids of the true and closest proposed isthmus areas. RESULTS: A total of 193 821 points were collected. Thirty isthmuses were detected in 29 tachycardias among 25 patients (median age 65.0, 5 women). The median (IQR) distance between true and the closest proposed isthmus area centroids was 8.2 (3.5, 14.4) mm in the training and 7.3 (2.8, 16.1) mm in the test group. The mean overlap in areas, measured by the Dice coefficient, was 11.5 ± 3.2% in the training group and 13.9 ± 4.6% in the test group. CONCLUSION: A GCN can be trained to identify isthmus areas in SRRATs and may help identify critical ablation targets.
Subject(s)
Action Potentials , Catheter Ablation , Cicatrix , Electrophysiologic Techniques, Cardiac , Heart Rate , Predictive Value of Tests , Tachycardia, Supraventricular , Humans , Female , Male , Cicatrix/physiopathology , Cicatrix/diagnosis , Middle Aged , Aged , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/etiology , Automation , Machine Learning , Treatment Outcome , Signal Processing, Computer-AssistedSubject(s)
Action Potentials , Cardiac Pacing, Artificial , Electrophysiologic Techniques, Cardiac , Heart Rate , Tachycardia, Supraventricular , Humans , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/therapy , Male , Electrocardiography , Treatment Outcome , Female , Middle AgedABSTRACT
BACKGROUND: Patients with Adrenal Insufficiency (AI) face elevated cardiovascular risks, but little remains known about arrhythmia outcomes in this context. METHOD: Analyzing the 2016-2019 Nationwide Inpatient Sample, we identified cases of Atrial Fibrillation, Atrial Flutter, and paroxysmal supraventricular tachycardia (PSVT) with a secondary diagnosis of AI. Mortality was the primary outcome while vasopressors and/or mechanical ventilation use, length of stay (LOS), and total hospitalization charges (THC) constituted secondary outcomes. Multivariate linear and logistic regression models were used to adjust for confounders. RESULTS: Among patients with Atrial Fibrillation, Atrial Flutter, and PSVT (N=1,556,769), 0.2% had AI. AI was associated with higher mortality (adjusted OR [aOR] 2.29, p=0.001), vasopressor and/or mechanical ventilation use (aOR 2.54, p<0.001), THC ($62,347 vs. $41,627, p<0.001) and longer LOS (4.4 vs. 3.2 days, p<0.001) compared to no AI. CONCLUSION: AI was associated with higher adverse outcomes in cases of Atrial Fibrillation, Atrial Flutter, and PSVT.
Subject(s)
Adrenal Insufficiency , Atrial Fibrillation , Atrial Flutter , Tachycardia, Supraventricular , Humans , Male , Female , Atrial Fibrillation/therapy , Atrial Fibrillation/epidemiology , Atrial Flutter/therapy , Atrial Flutter/epidemiology , Aged , Middle Aged , Tachycardia, Supraventricular/epidemiology , Tachycardia, Supraventricular/therapy , Tachycardia, Supraventricular/etiology , Tachycardia, Supraventricular/diagnosis , Adrenal Insufficiency/epidemiology , Adrenal Insufficiency/diagnosis , United States/epidemiology , Retrospective Studies , Length of Stay/statistics & numerical data , Risk Factors , Tachycardia, Paroxysmal/physiopathology , Tachycardia, Paroxysmal/therapy , Tachycardia, Paroxysmal/diagnosisABSTRACT
A case of successful catheter ablation of paroxysmal atrial fibrillation and atrial tachycardia is reported. After pulmonary vein isolation, atrial tachycardia was induced by the use of isoproterenol and burst pacing from the catheter in the right atrium. An attempt was made to create a three-dimensional (3D) map of the atrial tachycardia, but the atrial tachycardia was terminated in the middle of the mapping. The 3D map was insufficient but indicated that the superior vena cava was involved in the circuit. When the intracardiac electrograms were reviewed, it was found that the atrial tachycardia was initiated with orthodromic capture of superior vena cava potentials and it was considered that the atrial tachycardia involved the superior vena cava-right atrium junction. Accordingly, superior vena cava isolation was performed. After that, atrial fibrillation and atrial tachycardias were not induced by the use of isoproterenol and burst pacing. In this case, an intracardiac electrogram at the time of induction of the tachycardia was helpful for understanding the circuit of the tachycardia.
Subject(s)
Catheter Ablation , Vena Cava, Superior , Humans , Catheter Ablation/methods , Vena Cava, Superior/surgery , Male , Treatment Outcome , Atrial Fibrillation/surgery , Middle Aged , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnosis , FemaleABSTRACT
INTRODUCTION: The unique safety profile of pulsed field ablation (PFA) has made pulmonary vein isolation (PVI) + left atrial posterior wall (LAPW) ablation promising for treating persistent atrial fibrillation (PerAF). The goal of this study was to assess long-term freedom from atrial fibrillation, atrial flutter, and atrial tachycardia (AF/AFL/AT), as well as the safety and feasibility of LAPW PFA using multipolar, pentaspline Farawave catheter. METHODS: Retrospective observational study at a single institution. Data for 94 patients were collected from a prespecified intraprocedural registry. The long-term AF/AFL/AT recurrence assessment was based on an analysis of medical history; 24-h Holter ECGs at 3, 6, and 12 months postablation; and 12-lead ECGs recorded during symptomatic episodes or visits. RESULTS: Half of the patients had ls-PerAF, and half had a history of catheter ablation-mostly RF PVI. The acute ablation success rate was 100%, and the primary safety outcome was observed in 2 patients. Fifty patients experienced AF/AFL/AT recurrence (54.3%). An increase in LAPW low-voltage areas and AF classification were associated with arrhythmia recurrence. After a median follow-up of 13 months, the KaplanâMeier estimated median time free of AF/AFL/AT after a single procedure was 14.7 months. CONCLUSION: PFA PVI + PWA had the best outcome in perAF patients without extensive LA fibrosis. AF recurrence was paroxysmal in significant part of the cohort. The addition of PWA to PVI using multipolar PFA was safe and did not significantly influence the transpired ablation time.
Subject(s)
Action Potentials , Atrial Fibrillation , Catheter Ablation , Heart Rate , Pulmonary Veins , Recurrence , Humans , Atrial Fibrillation/surgery , Atrial Fibrillation/physiopathology , Atrial Fibrillation/diagnosis , Male , Female , Retrospective Studies , Middle Aged , Aged , Pulmonary Veins/surgery , Pulmonary Veins/physiopathology , Catheter Ablation/adverse effects , Time Factors , Risk Factors , Registries , Feasibility Studies , Treatment Outcome , Progression-Free Survival , Atrial Flutter/surgery , Atrial Flutter/physiopathology , Atrial Flutter/diagnosis , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/diagnosis , Heart Atria/physiopathology , Heart Atria/surgery , Cardiac CathetersSubject(s)
Diverticulum , Heart Atria , Humans , Diverticulum/complications , Diverticulum/diagnostic imaging , Heart Atria/diagnostic imaging , Heart Atria/abnormalities , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/etiology , Heart Diseases/diagnostic imaging , Heart Diseases/complications , Heart Diseases/diagnosis , Male , Female , Middle Aged , ElectrocardiographySubject(s)
Atrial Fibrillation , Catheter Ablation , Heart Defects, Congenital , Tachycardia, Supraventricular , Humans , Atrial Fibrillation/surgery , Atrial Fibrillation/physiopathology , Atrial Fibrillation/diagnosis , Heart Defects, Congenital/surgery , Heart Defects, Congenital/physiopathology , Heart Defects, Congenital/complications , Adult , Male , Female , Treatment Outcome , Tachycardia, Supraventricular/physiopathology , Tachycardia, Supraventricular/surgery , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/etiology , Middle Aged , Heart RateABSTRACT
INTRODUCTION: Left atrial (LA) low voltage areas (LVA) are a controversial target in atrial fibrillation ablation procedures. However, LVA and LA volume are good predictors of arrhythmia recurrence in ablation-naïve patients. Their predictive value in progressively diseased pre-ablated atria is uncertain. METHODS: Consecutive patients with recurrent atrial fibrillation (AF) or atrial tachycardia (AT), who were scheduled for repeat LA ablation, were enrolled in the prospective Bernau ablation registry between 2016 and 2020. All patients received a complete LA ultrahigh-density map before ablation. Maps were analyzed for LA size, LVA percentage and distribution. The predictive value of demographic, anatomic, and mapping variables on AF recurrence was analyzed. RESULTS: 160 patients (50.6% male, 1.3 pre-ablations, 60% persistent AF) with complete LA voltage maps were included. Mean follow-up time was 16 ± 11 months. Mean recorded electrograms (EGMs) per map were 9754 ± 5808, mean LA volume was 176.1 ± 35.9 ml and mean rate of LVAs <0.5 mV was 30.6% ± 23.1%. During follow-up recurrence rate of AF or AT >30 s was 55.6%. Patients with recurrence had a significant higher percentage of LVAs (40.0% vs. 18.8%, p < .001) but no relevant difference in LA volume (172 vs. 178 mL, p = .299). ROC curves revealed LVA as a good predictor for recurrence (AUC = 0.79, p < .001) and a cut-off of 22% LVAs with highest sensitivity (73.0%) and specificity (71.8%). Based on this cut off, event free survival was significantly higher in the Low LVA group (p < .01). CONCLUSION: Total LVA percentage has a good predictive power on arrhythmia recurrence in a cohort of advanced scarred left atria in repeat procedures independent of the applied ablation strategy. Left atrial volume seems to have minor impact on the rhythm outcome in our study cohort.